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Abstract
Chimeric antigen receptor (CAR) T cell therapy is an emerging cancer treatment that has
shown remarkable success in the treatment of B cell malignancies. However, this therapy still
has the potential to cause severe toxicities or poor treatment responses in some patients. An
imaging tool for tracking CAR-T cells could provide important patient-specific data on CART cell fate. In chapter 2, fluorine-19 magnetic resonance imaging (19F MRI) was evaluated as
a method to track the location of
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F perfluorocarbon (PFC) labeled CAR-T cells non-

invasively in a mouse model of B cell leukemia. We show for the first time that PFC labeled
CAR-T cells can be detected with a 3 Tesla clinical MR scanner and that PFC labeled CART cells show no significant difference in treatment response compared to unlabeled CAR-T
cells as evaluated with bioluminescence imaging. Chapter 3 summarizes the study and
discusses the limitations and future work.
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Summary for Lay Audience
Chimeric antigen receptor T (CAR-T) cell therapy involves taking immune cells from a
patient’s blood, reprogramming them to bind and kill cancer cells, and then injecting them
back into the patient. This treatment has shown a lot of success in patients battling blood
cancers such as leukemia, but current therapies still face problems such as harmful side
effects and ineffective treatment of solid tumours. My project is to implement imaging
techniques to track the fate of CAR-T cells after they have been injected into the body. Our
technique will use fluorine-19 magnetic resonance imaging to allow us to see the location of
the cells over time. Our methods will be useful for learning more about the negative
treatment responses to CAR-T cell therapy and for building and assessing new CAR-T cell
therapies that are safer and more effective against cancer. Importantly, this CAR-T cell
tracking method should be highly translatable for use in patients receiving CAR-T cell
therapies. This may eventually allow doctors to determine if the therapy will be effective at
earlier time points so that they can continue or change the treatment plan, to better determine
if a patient will have harmful side effects, as well as to better understand why the treatment
might fail or succeed in certain patients.
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Chapter 1

1

Introduction

This thesis develops and advances methods for tracking CAR-T cell therapies using
fluorine-19 (19F) magnetic resonance imaging (MRI) in a mouse model of B cell
leukemia. The introductory chapter discusses B cell malignancies, T cell therapies, proton
(1H) MRI and 19F MRI, and bioluminescence imaging (BLI) techniques for cell detection.
The purpose of the introductory chapter is to provide an introduction and motivation for
the research project presented in this thesis.

1.1 Motivation and Overview
Cancer is a devastating disease with over 617 Canadians diagnosed every day1. Current
standard of care cancer treatments have improved patient outcomes in many cases, but
there is still a large proportion of patients that do not survive for more than 5 years after
their initial diagnosis. Cell-based immunotherapies are a relatively newer way to treat
cancer by taking advantage of the natural functions of viable immune cells to target and
kill cancer cells. These therapies often aim to boost the immune system’s response to
cancer by having immune cells travel to cancer sites and mount an anti-tumor immune
response. Chimeric antigen receptor (CAR) T cell therapies in particular have shown
tremendous potential in patients leading to increased excitement about the potential for
cell therapies to be a powerful option to treat many cancer subtypes2,3. Unfortunately,
these therapies still have a tendency to cause unwanted and sometimes serious side
effects. In addition, some patients with blood cancers still show weak or no response to
CAR-T cells and they are still showing disappointing results against solid tumours.
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Current cell therapy monitoring in clinical trials relies heavily on blood tests and indirect
measures of tumour size over time. These measures are unable to provide any
information on the biodistribution of therapeutic cells or the number of cells in various
important organs during treatment. Imaging methods to detect the locations and number
of cells in the body would be extremely valuable for learning about therapeutic cell
behaviours during negative side effects and treatment outcomes.
In this thesis,

19

F MRI is used to detect CAR-T cells over time after intratumoural

administration. Chapter 1 provides an overview of the background and motivation
relevant to the work presented in this thesis. Chapter 2 examines the use of

19

F MRI to

detect perfluorocarbon (PFC) labeled CAR-T cells in a mouse model of B cell leukemia
using a 3 Tesla (T) clinical scanner. It also compares the treatment response in mice
administered PFC labeled (PFC+) CAR-T cells compared to mice that received unlabeled
CAR-T cells using BLI. Chapter 3 summarizes the work in this thesis and its
significance, expands on the limitations of this work, and discusses future work related to
the results presented in this thesis.

1.2 B Cell Malignancies
Hematological (blood) cancer, including B cell malignancies, are the fourth most
commonly diagnosed cancer type in Canada4. Additionally, B cell malignancies are
starting to affect more Canadians each year as the prevalence of these cancers increased
by 25% between 2014 and 2016. These cancers are particularly devastating as they are
one of the most common cancers found in children5. B cell malignancies are
characterized by their origin in B lymphocytes and are often referred to as “liquid
cancers” due to their occurrence in the blood and lymph. B cells are an important
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leukocyte population in the body that protect against pathogens by producing antibodies
and releasing cytokines6. B cell malignancies develop when B cells begin to expand
rapidly and continue to grow past their normal life cycle, leading to the crowding of
healthy cells. Patients often experience fever, frequent infections, and fatigue due to the
accumulation and improper functioning of B cells in their body7. B cell malignancies are
subdivided into B cell leukemia and B cell lymphoma based on the characteristics of the
disease.

1.2.1

B Cell Leukemia

B cell leukemia subtypes usually start in the bone marrow and are found in the blood,
bone marrow, and spleen of patients8,9. The two main types of B cell leukemias are B cell
acute lymphoblastic leukemia (ALL) and B cell chronic lymphocytic leukemia (CLL).
They are classified according to their rate of growth and their origin in the body. Chronic
lymphocytic leukemia is characterized by abnormal mature B cell behaviour in the blood
and develops more slowly10. In comparison, acute lymphocytic leukemia develops more
quickly as it is characterized by genetic mutations in immature B cells that cause them to
stop maturing and continually proliferate11.
When patients present with symptoms such as bone pain, bleeding gums or nosebleeds,
fever, or frequent infections they may be tested for leukemia. Leukemia is most often
diagnosed using blood tests or bone marrow biopsies. There are approximately 6 000 new
diagnoses of leukemia per year in Canada alone. Staging for ALL is dependent on the
maturity of the B cell and staging for CLL is based on the Rai system12. The Rai system
for CLL is dependent on the number of cancer cells in the blood, the degree to which the
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spleen and lymph nodes are involved, and whether the patient has developed comorbidities such as anemia and thrombocytopenia13. Currently, after diagnosis most
patients with leukemia undergo chemotherapy, radiation therapy, or stem cell
transplants14. Leukemia tends to progress more quickly than lymphoma giving patients a
slightly worse prognosis. The success rates for leukemia treatments show that
approximately 61% of patients recover after treatment. The success rates are much less
promising if the cancer recurs though. In addition, the 5-year survival rate for patients
diagnosed with leukemia is only about 58% which is quite low compared to other cancers
such as breast cancer (80%), thyroid cancer (95%), and prostate cancer (81%)15.

1.2.2

B cell Lymphoma

B cell lymphomas are cancers that are found in the lymph nodes or other lymphatic
tissues when too many abnormal B cells are developed16. There are two classifications of
lymphoma called Hodgkin’s lymphoma (HL) and Non-Hodgkin’s lymphoma (NHL). B
cell Hodgkin’s lymphoma is characterized by abnormal large B cells called Hodgkin and
Reed-Sternberg cells in the lymphatic system17. Non-Hodgkin’s B cell lymphoma is
simply characterized by the abnormal growth of B cells that are not classified as Hodgkin
and Reed-Sternberg cells in the lymphatic system18.
When patients present with symptoms such as fatigue, weight loss, fever, or many other
non-specific symptoms they may be tested for lymphoma. Lymphoma is most often
diagnosed by taking a biopsy of the affected lymph node(s). There are approximately 9
000 new diagnoses of lymphoma per year in Canada making it more common than
leukemia. Lymphoma is staged according to the number of sites that it has reached. Stage
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I lymphoma is only present in one lymphatic site, stage II is found in two or more sites
above the diaphragm, stage III is found in sites below the diaphragm, and stage IV is
found in organs outside of the lymphatic system. After diagnosis patients with lymphoma
may undergo chemotherapy, radiation therapy, stem cell transplants, surgery, or be
administered drugs that prevent additional growth of abnormal cells. Patients diagnosed
with B cell lymphoma have a slightly better prognosis than patients diagnosed with
leukemia due to the slower progression of the disease. In general, approximately 70% of
patients with lymphoma recover after treatment and the 5-year survival for HL is 85%
and NHL is 66%15. Unfortunately, like leukemia, if the cancer recurs the chance of
survival is greatly diminished. Treatments that could allow even larger proportions of
patients diagnosed with B cell malignancies to recover and improve the outcomes of
patients that experience recurrence would be extremely valuable. For this reason, it is
important to continue to study therapies for B cell malignancies so that we can further
improve the treatment outcomes of these patient populations.

1.3

T Cells

T cells are another type of leukocyte or white blood cell that acts as a specialized immune
cell in the body19. The immune system provides our body with protection from bacteria,
viruses, fungi, and other toxins. T cells specifically respond to foreign antigens present in
the body to protect against virus infected and transformed cells. T cells are made in the
bone marrow and then differentiate into cytotoxic (CD8) or helper (CD4) T cells in the
thymus, hence their name. Figure 1.1 illustrates the mechanisms of action that T cells
take to kill infected cells in the body. CD4 T cells protect the body from infection by
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releasing cytokines such as IFN-g, TNFa, IL-12, IL-4, IL-5, and IL-13 when they
encounter antigens, which then activates other immune cells to orchestrate an immune
response specific to the invader20. CD8 T cells directly bind to cancer cells or infected
cells to kill them through the Fas/Fas ligand pathway or, more commonly, the
perforin/granzyme pathway21. Briefly, the perforin/granzyme pathway is when activated
cells secrete the membrane disrupting protein perforin and the serine proteases called
granzymes by exocytosis causing apoptosis of the target cell22. The Fas/Fas ligand
pathway occurs when the Fas ligates to FasL and starts a cascade that leads to cell
apoptosis23. These cytotoxic functions only occur after the T cells have been activated
which naturally occurs when two conditions are met. The first condition is that the T cell
receptor (TCR) must bind to an antigen presented on a major histocompatibility complex
(MHC) of an antigen presenting cell (APC). The second condition is that a CD28
molecule on the T cell must bind to a CD80 or CD86 molecule on the APC, or in some
cases CD8 T cells can be activated by co-stimulation with CD70 or CD137 (4-1BB)24. In
addition, co-stimulatory receptors such as 4-1BB, OX40, and ICOS can ensure survival
of the T cell as long as the T cell strongly recognizes the antigen on the APC. The ability
of T cells to recognize and respond to transformed cells is crucial for humans to remain
cancer free. Unfortunately, cancer cells can evade T cell responses by downregulating the
MHC class 1 molecules, inhibiting apoptotic pathways, and inducing anergy in T cells
which allows them to tolerate cancer cell presence25. Once this occurs, T cells cannot
continue to recognize cancer cells and mount an effective cytotoxic response leading to
uncontrolled cancer cell growth.

7

Figure 1.1: Effector T cell killing mechanisms. (1) Perforin (PFN)/granzyme (GzmB)
pathway. (2) Fas Ligand (FasL)/Fas receptor pathway. (3) Release of cytokines such
as IFNg and TNFa.
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1.3.1

T Cell Immunotherapies

T cell immunotherapies are a relatively new class of cancer treatment that takes
advantage of the natural cytotoxicity of T cells. T cells are removed from a patient and
modified ex vivo to give them advantages over naturally occurring T cells in the body
before they are adoptively transferred back into patients26. T cell therapies were first used
to treat cancer patients in 1988 and since then many variations of T cell therapies have
been developed and tested27. Most notably there is tumour infiltrating lymphocyte (TIL)
therapy, cancer antigen-induced specific T cell therapy, and engineered TCR T cell
therapy. TIL therapy was the first T cell therapy developed and tested in patients28, 29.
They are produced by taking T cells from surgically resected tumours, isolating the TILs
that show reactivity to cancer cells ex-vivo, and then expanding these TILs to produce a
large population of tumour fighting T cells. This population of TILs is then re-infused
into the patient to boost the T cell response against cancer cells. They have shown
moderate responses in patients with melanoma with up to 50% response rates in patients
when lymphodepleting chemotherapy was used, but only a 20% complete response rate
was achieved30. Similarly, cancer antigen-induced specific T cells can be used to fight
cancer by making a cancer specific population of T cells ex vivo for adoptive transfer31,32.
Cancer antigen-induced specific T cells are made by isolating T cells from patient
peripheral mononuclear blood cells (PBMCs) or from resected tumours and then
activating them with antigen presenting cells that present cancer antigens specific to the
patient’s tumour type. Like TILs, this therapy has shown some success in patients with
metastatic melanoma33. The advantage of antigen-induced specific T cells over TILs is
that they are easier to produce as patient T cells can be isolated from blood instead of a
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tumour biopsy. Finally, engineered TCR T cell therapies are most often produced by
isolating T cells from patient PBMCs, cloning an antigen specific TCR that was found in
the patient’s PBMCs or TILs, engineering the T cells to express the cancer specific TCR
using lentivirus or gamma retroviruses, and then expanding this population before reinfusion34. The antigen specific TCR can also be produced by treating transgenic mice
with cancer antigen. Clinical trials treating melanoma and colorectal cancer have shown
some promise in the past with few reported toxicities35,

36

. Unfortunately, the natural

binding affinity of TCRs against cancer specific antigens is generally still low and there
is the potential for severe side effects depending on the TCR chosen. Altogether,
although there have been some successful outcomes using these T cell therapies in
clinical trials, they are very time consuming to produce and tend to only elicit an effective
response in a small portion of patients37. CAR-T cells were recently developed to
overcome some of the main limitations of previous T cell therapies by using custom
designed receptors to specifically target cancer antigens.

1.4

Chimeric Antigen Receptor (CAR) T cells

CARs were first proposed by Gross et al. in 198938. The goal of the CAR is to
accomplish specific targeting and killing of cancer cells by allowing for MHC
independent target recognition and activation of T cells. As mentioned above, T cells are
usually activated by an APC and then recognize cancer cells by binding to an antigen
presented on an MHC molecule39. This is often exploited by cancer cells as they can
evade the immune system by downregulating their MHC-associated antigen presentation.
In contrast, CAR-T cells recognize cancer cells independently of the MHC by directly
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binding to a tumour associated antigen (TAA) that is specific to the CAR40. CARs are
fusion proteins that mediate T cell activation using a recognition domain and T cell
signaling domains independent of the TCR (Figure 1.2). This allows for more timely
activation of T cells directly in the presence of cancer cells and fewer instances of tumour
escape41. After activation, CAR-T cells can either directly kill cancer cells using the
perforin and granzyme axis or the Fas and Fas ligand axis, or indirectly kill cancer cells
by releasing cytokines that recruit other immune cells. Studies have shown that both CD4
and CD8 CAR-T cells most often exhibit cytotoxicity through the perforin and granzyme
pathway42. CD4 CAR-T cells express lower amounts of perforin and granzyme causing
their cytotoxic response to be delayed compared to CD8 CAR-T cells. Despite their
delayed target cell response, studies have shown that both subsets are important for
proper target cell killing and that they kill equal amounts of tumour cells in vivo43. The
ability of a CAR-T cell to persist in the body and continuously fight cancer is highly
dependent on the components of their CAR which is further discussed below.
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Figure 1.2: T cell and CAR-T cell activation and survival signaling. (a) T cells are
activated by MHC interaction with the TCR (signal 1) and co-stimulation by CD80CD28 interaction (signal 2). (b) CAR-T cells are more easily activated as they only
require antigen specific interaction with a tumour associated antigen (eg. CD19).
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1.4.1

CAR Design

Generally, CARs accomplish antigen specific activation using an extracellular domain, a
transmembrane domain, and an intracellular signaling domain. The extracellular domain
contains the antigen recognition domain that most often consists of a single chain
variable fragment (scFv) derived from monoclonal antibodies to target a TAA. Recently a
synthetic version of an antibody targeting domain has been developed that could be used
in place of an scFv called designed ankyrin repeat proteins (DARPins)44. They may be
advantageous because they are smaller, extremely stable, and can be used to make multispecific CARs which is a growing area of research. The transmembrane domain spans the
cell membrane and is essential for transmission of the receptor-binding signal after the
extracellular domain binds a TAA. Finally, the signaling domain is made up of a CD3-z
subunit derived from the signaling domain in a TCR. It undergoes conformational
changes when the CAR binds to a TAA allowing for downstream activation of the T
cell45. The CAR signaling domain may also include the signaling endodomains of costimulatory molecules to mimic the co-stimulation (signal 2) that occurs during APC
dependent T cell activation.

1.4.2

Generations of CAR-T cells

There are five generations of CAR-T cells to date with each generation offering
additional features than the generation before it. First-generation CARs only contain an
scFv and CD3-z signaling domain. Their lack of co-stimulatory molecules, a hallmark
part of T cell activation, caused them to have limited activation potential. Without proper
activation, first generation CAR-T cells had limited cytotoxicity and persistence46. This

13

limitation led researchers to develop the next generation CARs. Second generation CARs
were designed to include a co-stimulatory molecule in the intracellular signaling domain
to improve their activation potential and persistence47. The most common co-stimulatory
molecules used in CARs are 4-1BB and CD2848. The 4-1BB co-stimulatory molecule is
better at promoting long-term persistence of CAR-T cells and stimulating memory T cell
generation49. The CD28 co-stimulatory molecule is ideal for potent CAR-T cell
cytotoxicity and IL-2 production. Third generation CARs were developed next in an
attempt to further improve the signaling and survival of CAR-T cells. They contain two
co-stimulatory domains such as OX40 and CD28 instead of just one costimulatory
domain to enhance the survival of the CAR-T cells50. Current data is showing that
including two co-stimulatory domains does not appear to increase the efficacy of the
therapy compared to second generation CARs51. Fourth generation CAR-T cells, often
called TRUCKS (T cells redirected for antigen‐unrestricted cytokine‐initiated killing),
have been developed in an attempt to improve CAR-T cell efficacy against solid
tumours52. Fourth generation CARs use the framework from second-generation CARs
that contain only one co-stimulatory molecule. They combine the CAR response with a
nuclear factor of activated T cells (NFAT) domain that releases cytokines such as IL-12
to

make

CAR-T

cells

more

resistant

to

the

immunosuppressive

tumour

microenvironment53. Recently, fifth generation CARs were developed to try to further
improve the survival of CAR-T cells. They use the framework of a second-generation
CAR with the addition of a fragment of IL-2 receptor b (IL-2Rb) that can bind to
STAT354. This domain is able to activate the JAK-STAT pathway which is important for
preventing terminal differentiation of the T cells. Overall, there are still many studies
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needed to fully understand the mechanisms of activation and cell death achieved by
CAR-T cells, but their potential is undeniable based on clinical trials.

1.4.3

CAR-T Cell Production

CAR-T cell therapies are produced in current good manufacturing practice (cGMP)
facilities that are equipped to ensure patients are receiving sterile and high-quality
therapies55. Figure 1.3 illustrates the CAR-T cell manufacturing steps. Autologous T cells
are most often used for CAR-T cell production to avoid graft versus host disease56. T cell
collection begins with leukapheresis which is a process that removes leukocytes
including T cells from the patient’s blood before returning the blood back to the patient57.
Once T cells have been isolated, they are expanded by activating them through their T
cell receptor (signal 1) and their co-stimulatory domain (signal 2). Multiple companies
sell products for T cell activation such as CD3/CD28 antibody coated magnetic beads,
antibody coated nanobeads, anti-CD3 antibodies, expamer technology, and antigen
presenting cells. CD3/CD28 coupled magnetic beads called Dynabeads were used in this
thesis as a convenient and easily removable method for T cell activation58. In addition, T
cells are cultured in media supplemented with IL-2 to encourage proliferation. After
activation, T cells are genetically modified to express a CAR specific to the patient’s
cancer type. Stable CAR expression in T cells is most often accomplished using lentiviral
or gamma retroviral vector transduction59. Gamma-retroviral vectors were the first
method used to generate CD19 CAR-T cells for clinical use. Gamma-retroviruses are a
valuable option for clinical CAR-T production because they are easier to produce, but
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they can only transduce dividing cell populations and they pose a larger risk for
insertional oncogenesis60. Currently, the most popular method for CAR transduction in
clinical trials is lentiviral vectors61. Lentiviral transduction can be performed in any phase
of the cell cycle and their gene integration occurs in safer locations compared to other
viral transduction methods. After transduction, the engineered CAR-T cells need to be
expanded to obtain large populations for adoptive transfer. For clinical manufacturing of
CAR-T cells, billions of CAR-T cells are required which has led to the use of bioreactors
that mimic ideal body conditions for cell growth62. Bioreactors are capable of
consistently feeding the cells, removing waste, and rocking the cells back and forth to
achieve gas transfer allowing for rapid expansion of CAR-T cells. After expansion, the
CAR-T cells are used for treatment as long as they pass all of the safety, identity, and
purity testing checkpoints during production63. The production and characterization of
CAR-T cells is largely the same regardless of the CAR that is being used in the study.
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Figure 1.3: CAR-T cell production process. Blood is removed from a patient and
then T cells are isolated from the blood. Next, T cells are engineered to express an
antigen specific CAR and then expanded. After expansion, the CAR-T cells are
delivered to the patient for cancer treatment.
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1.4.4

CAR-T Cell Administration

Patients are often treated with chemotherapy for lymphodepletion prior to CAR-T cell
adoptive transfer64. Lymphodepletion is the destruction of lymphocytes including T cells,
B cells, and NK cells in the body. It helps in adoptive cell transfer-based therapies by
removing regulatory T cells, suppressing the patient’s immune system, and activating
antigen presenting cells. Once lymphodepletion is performed, that patient is ready for
their CAR-T cell infusion. The CAR-T cell dose that patients receive ranges from 1 × 104
to 1 × 1010 cells/kg in clinical studies and they are most often administered intravenously
(IV) in one dose using a slow infusion65, 66. Studies have also begun to test the efficacy of
local or intratumoural (IT) injections of CAR-T cells or injecting the CAR-T cells in
multiple slow infusions at different time points67, 68. Ideally, CAR-T cells should remain
in the patient after injection until the cancer is eradicated69. Tests have shown that they
can survive anywhere from 6 weeks to 5 years in patients, although more consistent
follow ups with patients after treatment will continue to improve this data70-72.

1.4.5

CAR-T Cell Therapy Outcomes

There have been many TAA specific CAR-T cells studied to target a large variety of
cancer types since the first development of CAR-T cells. The most notable CAR-T cell
therapies to date are second generation CD19 targeting CAR T cells as they were the first
to make it to large scale clinical trials in patients. They target the CD19 antigen that is
found in low levels on normal B cells but is over expressed on B cell malignancies. CD19
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is an ideal target because it is only expressed by B cells which means off-target cell
killing during treatment will be contained to the B cell population73. Most clinical studies
use different variations of CD19 CAR-T cells which has an effect on the outcome of the
study. In general, CD19-CAR-T cells are showing a response rate (RR) of 72% in
patients with B cell malignancies across all clinical trials which is especially impressive
as these patients did not respond to or relapsed after traditional cancer treatments74. In
particular, patients with B cell ALL have shown amazing results with complete remission
(CR) rates of up to 93% in recent clinical trials75. Interestingly, comparisons between CR
rates in a recent systematic review of CD19 CAR-T cell clinical trials treating ALL
showed a difference between the treatment outcomes in patients treated with 4-1BB
containing CARs (CR=86%) compared to CD28 containing CARs (CR=74%)76. In
addition, diffuse large B-cell lymphoma (DLBCL), which is a form of NHL, has shown
impressive CR rates of approximately 54% in patients with refractory disease using
CD19 CAR-T cells77. These trials resulted in Health Canada approval of two second
generation CD19 CARs for the treatment of specific B cell malignancies. Kymriah
(CTL019, Tisagenlecleucel) developed by Novartis was the first CAR approved by
Health Canada in 2018 to treat children and young adults with B cell ALL who relapse or
are not eligible for stem cell transplants. Yescarta (KTE-C19, Axicabtagen ciloleucel)
developed by Kite/Gilead was approved next by Health Canada in 2019 to treat patients
with relapsed or refractory DLBCL. These therapies differ slightly as Kymriah is 4-1BB
driven and engineered using lentivirus and Yescarta is CD28 driven and engineered using
retrovirus78, 79. Since their approval, developments have begun to create opportunities for
the production and use of these therapies in Canada. In addition to CAR-T cells that
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target B cell malignancies, there have also been minor successes in clinical trials using
CAR-T cells that target solid tumours. For example, the use of GD2 targeting CAR-T
cells to fight neuroblastoma in a recent clinical trial led to response rates of
approximately 33%80. Overall, CAR-T cell therapies are still not showing very much
efficacy against solid tumours with an average response rate among clinical trials of 9%.

1.4.6

CAR-T Cell Limitations

CAR-T cell therapies tend to cause a range of side effects during treatment. Studies have
shown that over 85% of patients treated with CAR-T cells experience at least one adverse
event77. One of the common side effects during treatment is cytokine release syndrome
(CRS). CRS causes a range of symptoms that can be lethal in severe cases81. The
symptoms of CRS include fever, hypotension, organ dysfunction, and increasing oxygen
requirements of the body. The cause of CRS has been linked to high levels of cytokines
such as interleukin-6 which may be elevated directly due to the anti-tumour response of
CAR-T cells. Another common side effect after CAR-T cell transfer is tumour lysis
syndrome82. Tumour lysis syndrome describes the metabolic complications that occur
due to the breakdown of a large number of dying cells. Most often patients experience
acute kidney failure, cardiac dysfunction, seizures, or nausea. Patients may also
experience neurotoxicity during CAR-T cell treatment which also ranges in severity but
tends to cause encephalopathy, seizures, delirium, agitation, and headaches83. In addition
to the side effects caused by CAR-T cells, there are also direct cytotoxicities caused by
CAR-T cells acting on healthy cell populations in patients84. On target/off tumour CAR-T
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cell responses are extremely common as most TAAs are also expressed at lower levels on
healthy cells in the human body. In the case of CD19 targeting CAR-T cells, CD19 is an
excellent TAA because it is overexpressed on B cell malignancies, but it is also expressed
on healthy B cells. Therefore, during treatment with CD19 CAR-T cells the patients will
experience B cell aplasia85.
Another limitation of CD19 CAR-T cells is that they do not mount an effective response
in every patient. For example, there are still approximately 30% of patients with B cell
malignancies that do not respond to CD19 CAR-T cell therapies. Even in successful
cases, relapse still occurs in up to 50% of patients that responded to the therapy86. These
sub-optimal CAR-T cell responses may be due to a lack of CAR-T cell expansion or
persistence after injection, but there is limited patient specific data to support this87.
Although these values are still much more encouraging than the response rates of CAR-T
cells targeting solid tumours, further optimization of CD19 CAR-T cell therapies could
continue to improve patient outcomes.

1.4.7

CAR-T Cell Monitoring

In order to effectively optimize current and emerging CAR-T cell therapies, accurate data
on the fate of T cells needs to be available after injection. CAR-T cell monitoring is
required to gain knowledge of CAR-T cell biodistribution and persistence in patients and
learn how these characteristics correspond to treatment outcomes and side effects.
Currently, blood tests are used to monitor CAR-T cell response after adoptive transfer
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into patients88. These blood tests employ flow cytometry, polymerase chain reaction
(PCR), or a combination of both to determine the persistence and expansion of CAR-T
cells in the blood after injection. Blood tests are a relatively easy and cost-effective
method for determining number of circulating T cells, but they cannot provide any real
time information on the location of CAR-T cells in the body. This leads to a lack of data
on the number of CAR-T cells that have made it to cancer locations compared to the
number of CAR-T cells in off target locations. Minn et al. showed that the number of
circulating CAR-T cells detected using blood tests did not correlate to the number of
CAR-T cells that were present in tumours based on positron emission tomography (PET)
images89. This suggests that the number of CAR-T cells detected in peripheral blood may
not be a reliable method for predicting treatment response. In addition, blood tests are
unable to predict neurotoxicity or CRS severity at this time due to limited access to IL-6
testing and no current available markers for neurotoxicity90.
Studies have begun to look at molecular imaging techniques to complement current
clinical blood tests. The rationale is that they can provide patient specific information on
the location(s) and persistence of CAR-T cells during treatment. PET is a widely used
clinical imaging modality because of its high sensitivity and tissue penetration in
patients91.

Sellmyer et al. used PET to track escherichia coli dihydrofolate reductase

enzyme (eDHFR) expressing CAR-T cells in a mouse model of osteosarcoma after an
infusion of [18F]-trimethoprim (TMP)92. They successfully detected the presence of CART cells in cancer locations in mice over time. They also noticed that they could detect
CAR-T cells in the spleen at earlier timepoints before tumour invasion occurred. Minn et
al. used PET to track prostate-specific membrane antigen (PSMA) expressing CAR-T
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cells in a model of leukemia after an infusion of
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F-DCFPyL89. Early imaging time

points showed expansion of CAR-T cells in the bone marrow and later images showed
accumulation of CAR-T cells in the tumour proving that this imaging technique can
monitor treatment progression over time. A clinical study has also been performed by
Yaghoubi et al. to detect cytotoxic T lymphocytes (CTLs) that were labeled with herpes
simplex virus 1 thymidine kinase (HSVtk1) using 18F-FHBG and PET in a patient with
glioblastoma93. They were able to detect the intracranially injected CTLs 2 hours after an
injection of
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F-FHBG. They found that the CTLs had localized in the location of a

resected tumour as well as the new tumour that they were targeting. The images
confirmed that their injection was effective and that the cells were able to migrate to
tumour locations. Despite promising results with PET, there is often background uptake
of the tracer in organs such as the stomach, thyroid, and kidneys which may mask the
signal of CAR-T cells in these locations. In addition, longitudinal cell tracking studies are
limited using PET due to radiation dose concerns for both the patients and the adoptively
transferred cells94.
MRI may be advantageous over PET for CAR-T cell tracking as scans are performed
using non-ionizing radiation leading to fewer concerns when planning longitudinal cell
tracking ventures. MRI also has excellent soft tissue differentiation and resolution
compared to PET. Brewer et al. used MRI to track super paramagnetic iron oxide (SPIO)
nanoparticle labeled CTLs in a mouse model of cervical cancer95. They were able to
detect CTLs in the tumours 24 hours after injection and distinguish differences in the
location of the CTLs based on whether or not the mouse was given a cancer vaccine prior
to labeled CTL treatment. In addition, Lui et al. tracked T cells using MRI by labeling
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them with nano-sized iron oxide nanoparticles prior to injection. Their nanoparticle
achieved an impressive labeling efficiency of over 90% in T cells and enabled the
detection of the T cells in vivo96. Limitations of using iron oxides are that they cause
hypointensities in images. Hypointense regions are not specific to iron labeled cells and,
therefore, do not allow for quantification of adoptively transferred labeled cells. There
have not been any clinical studies tracking T cells with MRI to date, but there is a lot of
potential in this field as other therapeutic cell populations have been successfully tracked
using cellular MRI97-99. One of the most recent promising methods for tracking CAR-T
cells in clinical settings is fluorine-19 (19F) MRI which combines the anatomical
information of 1H MRI with the detailed “hotspot” imaging of 19F MRI.

1.5

Magnetic Resonance Imaging

MRI provides excellent soft tissue contrast allowing for the generation of highly detailed
anatomical images. MRI was successfully used to image human anatomy for the first
time in 1977 based on the principles of nuclear magnetic resonance (NMR)100. NMR
relies on the principle that nuclei in the presence of a magnetic field can absorb energy
from radiofrequency (RF) pulses that are generated at frequencies specific to the nuclei of
interest called the larmor frequency101. The absorbed energy is then dissipated to form
signal when the RF pulse is turned off. This detected signal can then be used to determine
the number of nuclei present in a sample as long as the properties of the sample such as
relaxation and chemical shift are known. MRI most commonly relies on the excitation of
protons (1H) to form signal102. 1H are the most widely used nuclei for MRI because they
make up a large portion of the human body and they have a high gyromagnetic ratio of
42.58 MHz/T. The three main components of an MR scanner are the magnet, the gradient
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coils, and the RF coil. Each of these parts work together to manipulate nuclei and in turn
obtain signal.

Many nuclei such as 1H naturally possess a quantum mechanical property called “spin”
(Figure 1.4A)103. These nuclei have a net magnetization vector (M) which is the sum of
all of the magnetic moments of each nuclei in a given region. When nuclei are not in a
magnetic field, they have a net magnetization vector of zero because the individual
magnetic moments are randomly oriented104. The magnet which can range between
clinical field strengths of 1.5-3 Tesla (T) or pre-clinical field strengths of 7-11.7T creates
a magnetic field that causes the nuclei to obtain a small non-zero net magnetization. Once
the majority of the nuclei align with the main magnetic field in the scanner, a RF pulse
can be applied to excite the nuclei, changing the orientation of the net magnetization
vector (Figure 1.4B)105. This net magnetization vector then relaxes back to equilibrium
via transverse relaxation and longitudinal relaxation which generates detectable signal
when the RF pulse is turned off (Figure 1.4C). Transverse relaxation is described by T2
which is the transverse relaxation time constant or spin-spin relaxation time constant. T2
relaxation describes the dephasing of spins caused by energy transfer between
neighbouring nuclei resulting in the decay of transverse magnetization. The transverse
magnetization decays exponentially with time as a result of the properties of tissues. The
longitudinal relaxation of the nuclei is described by T1 which is the longitudinal
relaxation constant or spin-lattice constant. Longitudinal magnetization recovers back to
equilibrium independently of the transverse magnetization. T1 relaxation describes the
transition of excited spins back to a lower energy states to achieve thermal equilibrium106.
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Figure 1.4: Nuclear precession and T1 and T2 Relaxation. (a) The behaviour of a proton
placed in a magnetic field (B0) where w0 is the Larmor frequency. (b) An RF pulse causes
excitation of the protons. When the RF pulse is removed, the protons relax through T1
and T2 relaxation. (c) A graphical representation of T1 (Longitudinal) and T2
(Transverse) relaxation.
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1.5.1
1

Image Contrast

H nuclei in different tissues relax at different rates which can be taken advantage of to

create contrast in MR images107. Contrast in MR images can be weighted depending on
proton density (PD), T1 relaxation time, or T2 relaxation time. PD weighted images have
higher signal in areas that are proton dense. T1 weighted images have higher signal in
regions with shorter T1 relaxation such as fat and lower signal in areas with longer T1
relaxation times such as water. T2 weighted images have higher signal in areas with a
longer T2 relaxation time such as fluid and lower signal in areas with shorter T2
relaxation times such as fat. Many tumours for example appear darker in T1 weighted
images and brighter in T2 weighted images.

1.5.2

Magnetic Field Gradients

Magnetic field gradients are essential for MRI because they allow for spatial localization
and encoding of information108. Gradient coils are independently pulsed to create small,
localized field gradients that can be used in conjunction with RF pulses to target the
excitation of spins to certain locations. To form an image, an anatomical slice is excited
in a plane of interest and then information encoding is applied along the other two
directions using frequency and phase encoding gradients. Generally, the plane of interest
is along the z direction, the phase encoding is along the y direction, and the frequency
encoding is along the x direction. Frequency encoding gradients change the larmor
frequency of the nuclei in a gradient along the x direction to elicit a signal that is based
on the location of the nuclei along the slice. Phase encoding gradients are turned on
independently of the frequency encoding gradients to change the larmor frequency in the
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y direction to provide additional information on the location of the nuclei based on their
phase. When RF pulses are turned off, all of this information is collected by
radiofrequency coils to create MR images.

1.5.3

Radiofrequency Coils

RF coils are responsible for the excitation and subsequent detection of energy from the
nuclei109. The two main RF coils are surface coils and volume coils110. Volume coils are
more commonly used because of their ability to obtain uniform signal that does not
depend on depth. In cases where deep tissues are being probed such as the head or knee it
is especially important to use a volume coil. Surface coils have higher sensitivity but
there is signal drop off as the distance between the coil and tissue is increased. Surface
coils are most often used for imaging superficial anatomy such as the spine or
temporomandibular joint. In this thesis, a surface coil was used as our imaging was
focused on subcutaneous tumours so signal drop off with imaging depth was not of
concern. In addition, the coil we used is dual tuned to enable 1H MRI and fluorine-19
(19F) MRI so it was important to maximize signal.

1.5.4

Pulse Sequences

Pulse sequences are a set of instructions for the RF coil and gradients to follow to
generate specific MR images. The main characteristics of a pulse sequence are time to
echo (TE), repetition time (TR), and flip angle (FA). Generally, TR is the time between
the start of an RF pulse and the start of the next RF pulse applied to the same slice, TE is
the time between the start of an RF pulse and the peak of the echo detected, and FA is the
angle of the pulse applied to flip the net magnetization vector. Spin echo (SE) and
gradient echo (GE) sequences are the most common pulse sequences. SE sequences are
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generally used to create T2 weighted images111. They are insensitive to magnetic field
inhomogeneity, which is useful for avoiding image artifacts, but the image acquisition
takes longer. GE sequences are faster because they have shorter TR, but they are more
sensitive to susceptibility artifacts. The sequence that our lab is most interested in is a GE
sequence called balanced steady state free precession (bSSFP). It is also referred to as
TrueFISP, FIESTA, or balanced FFE depending on the manufacturer of the MRI. The
bSSFP sequence begins with a fast train of pulse sequences that do not allow time for the
transverse relaxation to decay and thus, a steady state of magnetization is reached112. This
allows for high signal to noise ratio and fast image acquisition. bSSFP provides mixed
T2/T1 contrast images which limits some of the diagnostic uses of the sequence but still
provides useful anatomical images. Once the MRI protocol is completed, all of the
information that was collected into the MR system processor is automatically processed
using fourier transforms for image reconstruction. Post processing tools such as Horos or
Osirix can then be used to analyze image characteristics.
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1.6

F Magnetic Resonance Imaging

In addition to protons, there are other nuclei that can be used for MRI such as
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F,

Carbon-13, Sodium-23, and Phosphorus-31. Of these additional nuclei, 19F is considered
one of the best candidates for MRI because it has a gyromagnetic ratio of 40.08 MHz/T
and a sensitivity of 83% when compared to protons113. In addition, there are only trace
amounts of
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F in the bones and teeth of humans which is below the detection limits of

MRI allowing for background free “hotspot” imaging of 19F. The “hotspot” data can then
be overlayed onto 1H images to provide anatomical context114. 19F MRI was successfully

29

developed by Holland et al. in 1977 and since then has become a popular imaging
modality for cell tracking115. It has been used by multiple groups to provide valuable
information on adoptively transferred labeled cell populations116. 19F cellular MRI has the
advantage of specific, background free detection of
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F labeled cells. The “hot spot”

characteristic of 19F MRI is highly valuable when compared to other MRI contrast agents
including iron oxide nanoparticles that indirectly cause negative contrast in MR images
or manganese and gadolinium that indirectly cause positive contrast in MR images.
Although the sensitivity of 19F MRI is relatively low compared to other imaging methods,
it can still be used to detect thousands of labeled cells117.
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F MRI was proven to be

valuable for clinical cell tracking ventures when Ahrens et al. used it to detect
perfluorocarbon (PFC) labeled dendritic cells in patients118.
19

F MRI is performed on standard MR scanners using an RF pulse specific to the

resonant frequency of
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perform dual 1H and

F MRI by emitting and receiving at both frequencies. Since

19

F nuclei119. Specialized RF coils have been designed that can
19

F

MRI directly detects the spin density of 19F nuclei, the contrast in 19F images is based on
the density of

19

F nuclei per voxel in the body. The linear relationship between

19

F

content in a voxel and 19F signal and the lack of endogenous 19F signal in the body allows
19

F MRI to be quantitative120. The number of 19F spins in a given region of interest can be

calculated using the signal obtained from reference tubes containing a known amount of
19

F. If cells are labeled ex vivo prior to adoptive transfer, there is also the potential to

calculate cell number based on the

19

F images. Calculating cell number requires three

pieces of information: 1) The number of 19F spins per cell prior to injection as determined
by 19F NMR, 2) the signal obtained from the region of interest containing the 19F labeled
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cells in the MR image, 3) the signal obtained from the reference tubes with known

19

F

content121. One major limitation to the cell number quantification is that dividing cell
populations will not be accurately quantified over time.

1.6.1

Cell Labeling for 19F MRI

PFCs are tracer agents with a strong C-F bond making them stable at physiological pH
and non-toxic in humans122. They have historically been used in the clinic as blood
substitutes because of their ability to dissolve oxygen. They have also been co-opted by
imaging scientists as a cell label to enable cell detection with
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F MRI.

Perfluorooctylbromide (PFOB) was one of the first PFCs that was used extensively in
patients as a blood substitute and in clinical trials for inflammation and bowel imaging123.
Unfortunately, PFOBs showed 8 peaks in an NMR spectrum making SNR and image
quality worse. This led to the development and use of Perfluoropolyethers (PCPEs).
PCPEs have one main peak on a
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F NMR spectrum and they have high fluorine

content124. The ideal PFC tracer for clinical cell tracking would be commercially
available and extensively studied. While there are many different possible formulations
for 19F PCPEs, this thesis focuses on the chemically modified PCPEs made by CelSense
as they are commercially available and well-studied for in vivo cell tracking applications.
CelSense

19

F PFC emulsions have high fluorine content to enable

19

F MRI and are

available with fluorescence probes to enable detection with flow cytometry or
histochemistry. They also have a small diameter of 165nm and a slightly negative charge
to enable cell uptake by endocytosis125. They have been FDA approved in the United
States and used in clinical trials in patients126. They show very low toxicity in patients
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and no significant toxicities in many cell lines. Cell labeling is accomplished by simple
co-incubation of the PFCs and the cell of interest. After labeling, PFCs stay in a labeled
cell as long as the cell remains viable and is divided between daughter cells upon cell
division. When a labeled cell dies the label is released and quickly cleared by the
reticuloendothelial system (RES) to the liver where they will slowly be released into the
blood and exhaled127. There is also a chance that they may be taken up by phagocytic
bystander cells such as macrophages. Recently, Helfer et al. showed that labeling T cells
with 19F PFCs is possible at a large clinical scale without harming the final product128.

1.6.2
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CAR-T Cell Imaging with 19F MRI

F MRI has been used to detect the location and number of many immune cell types to

date129-131. In the past 5 years, CAR-T cells have been successfully labeled with 19F PFCs
and detected using 19F MRI in vivo. Below is a summary of recent advances in imaging
CAR-T cells using 19F MRI.
In 2017, Chapelin et al. were the first to PFC label CAR-T cells and confirm intracellular
localization of the PFC132. After successfully labeling the CAR-T cells without any
negative effects on the CAR-T cell phenotype, they injected them into a mouse model of
glioblastoma. The study showed that PFC+ CAR-T cells slow down the progression of
cancer in their model compared to mice that received untransduced T cells or no
treatment. They were also able to detect the presence of PFC labeled CAR-T cells in
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tissue samples of the liver, lungs, tail, spleen, lymph nodes, thymus, tumours, and
kidneys of treated mice up to 14 days post injection using ex vivo NMR.
Hingorani et al. used trans-activator of transcription (TAT) conjugated PFC
nanoemulsions to label and track CAR-T cells in a mouse model of glioma133. They
imaged the cells 24 hours after an intratumoural injection using an 11.7T scanner and
found that they could detect almost 100% of the injected cells. This study was the first to
show detection of PFC+ CAR-T cells with 19F MRI.
Very recently, Chapelin et al. imaged PFC+ CAR-T cells over time in a mouse model of
glioblastoma using an 11.7T MRI134. They were able to show for the first time that
intratumourally injected CAR-T cells could be detected in tumour sites using 19F MRI up
to day 10 post-treatment using an 11.7T scanner. They also looked at the intracellular
partial pressure dynamics of CAR-T cells using 19F MRI.
Each of these studies made important progress in CAR-T cell tracking using
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F MRI.

The main limitation for clinical translation of these studies is that they used field
strengths well above clinical standards to improve signal detection. The sensitivity is
improved at higher field strengths allowing for shorter scan times and fewer cells to be
detected. This thesis is focused on imaging PFC+ CAR-T cells using clinical 3 T MRI
and a human surface coil. By using clinical field strengths, we continue to gain valuable
information on this imaging technique that will improve the chances of clinical
implementation of CAR-T cell tracking using 19F MRI.
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1.7

Bioluminescence Imaging

Bioluminescence imaging (BLI) is a valuable pre-clinical imaging technique to track
proliferating cells over time in vivo. BLI reporter genes are stably expressed in cell
populations so that they are passed down to daughter cells during cell division which
allows them to be continually detected. BLI has been adapted by many researchers due to
its low cost, high sensitivity, and high specificity135. The BLI system is composed of a
black box imaging chamber with a heated stage where the subject is placed during
imaging and a cooled charged couple device (CCD) camera that collects the emitted light
from the subject. The system first acquires a photographic image for reference and then
overlays the detected BLI signal onto the photograph136. Imaging time can be
automatically determined by the BLI software and usually ranges from seconds to
minutes depending on the amount of signal coming from the subject. Tracking cells is of
particular interest using BLI because the characteristics of signal generation cause only
viable engineered cells to be detected. This is a characteristic of the enzymatic reaction
that takes place between the engineered cells and the injected substrate. For cell tracking
purposes, cells are engineered to stably express luciferase genes prior to injection into the
animal model. Bioluminescence images are then acquired by first administering the
substrate to the subject to produce signal from the engineered cells. Mice are then imaged
for up to 30 minutes after substrate administration until the peak signal is obtained. For
analysis, regions of interest (ROI) can be manually placed onto the images displayed in
the LivingImage software to assess the signal in the region. Longitudinal images can then
be assessed to determine the relative number of viable engineered cells over time and
their location(s). This is especially valuable when studying cancer therapies in pre-
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clinical models to determine if the relative number of viable cancer cells is decreasing
after treatment.

1.7.1

Genome engineering

For cell tracking studies, cells of interest are cultured ex vivo and engineered to stably
express a luciferase gene. Many luciferase enzymes have been isolated from different
species and made available for imaging purposes137. Renilla luciferase and firefly
luciferase (FLuc) are the most common transgenes for BLI. This thesis focuses on FLuc
as it has a more favourable injection route and has better light penetration through tissues
because its emission spectrum is more red shifted. When expressed, FLuc produces an
enzyme that reacts with the substate D-luciferin in the presence of oxygen and adenosine
triphosphate (ATP) to produce light138 (Figure 1.5). To accomplish stable gene
expression, cell populations need to be engineered prior to their injection. In the past, my
colleagues and I successfully used clustered regularly interspaced short palindromic
repeats and crispr associated protein 9 (CRISPR/Cas9) to integrate FLuc into a safe
harbour site in cells139. The greatest advantage of CRISPR/cas9 genome editing is that
gene integration is site specific which means safe sites can be targeted to avoid
behavioural modifications caused by insertional mutagenesis. Unfortunately, this process
is still fairly inefficient compared to largely used methods such as lentivirus and
gammaretrovirus transduction. Our lab and others have used lentivirus extensively to
make stable cell lines because it is cost-effective, efficient, and relatively safe. In this
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thesis we used lentivirus to produce FLuc expressing leukemia cells to enable the
tracking of their relative viability with longitudinal BLI.
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Figure 1.5: Bioluminescence Imaging (BLI) diagram depicting the reaction between
viable firefly luciferase expressing cancer cells and the substrate D-luciferin in the
presence of oxygen and ATP to produce light, AMP, carbon dioxide, and
oxyluciferin. The light is detected by the CCD camera to create an image.
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1.7.2

Cancer Cell Imaging with BLI

Cancer researchers rely heavily on methods that measure tumour burden when studying
new therapies. Caliper measurement is a commonly used metric for measuring tumour
volumes and is often used to determine the response of tumours to a new therapy140, 141.
Although this method is easy to implement and very cost effective, tumour necrosis can
occur much before a tumour changes in size. Therefore, if researchers are relying solely
on changes in size to evaluate a response to treatment it might prolong the study and
provide inaccurate estimates of how long it takes for the treatment to begin working. In
contrast, BLI is an ideal method for cancer detection in pre-clinical models because it is
cost-effective, specific to engineered cell populations, and only detects viable cells. BLI
is an extremely valuable imaging method for studying cancer cell growth and subsequent
treatment with therapies as signal is only produced by viable luciferase expressing
cells142. Cancer cell growth can be monitored prior to treatment to determine a baseline
for cancer signal. Downstream BLI post-treatment can then be used to monitor for cancer
cell death as there will be less signal if cancer cells die. Therefore, as necrosis occurs
tumour signal will decrease even if the volume does not change. Below are examples of
studies that have successfully used BLI to detect cancer cell viability and growth over
time in the presence of therapeutic cells.
Rehemtulla et al. used BLI as a method to assess the cancer treatment response to
chemotherapy142. They successfully imaged FLuc expressing glioma growth over time in
rats using BLI to detect differences in signal before and after treatment. Their data
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suggests that BLI may be a better measure of tumour burden over time compared to MRI
tumour volume measurements because BLI only measures metabolically active cells.
Parkins et al. used dual BLI to track RLuc expressing circulating tumour cells (CTC) that
were engineered to express a suicide gene and then adoptively transferred into mice
bearing FLuc expressing breast cancer143. We were able to compare the locations of the
therapeutic cells and the cancer cells over time. In addition, we could determine the CTC
treatment effect by comparing the BLI signal measurements over time.
Finally, two of the previously discussed studies that imaged PFC+ CAR-T cells used BLI
to evaluate the tumour response after treatment in combination with 19F MRI to evaluate
the CAR-T cell location132,
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. They found that PFC+ CAR-T cells cause significant

cancer cell death in mouse models of glioblastoma. Currently, no groups have looked at
the difference in treatment response between PFC+ CAR-T cells and unlabeled CAR-T
cells in vivo using BLI. This thesis focuses on determining if PFC+ CAR-T cells show
the same treatment effect in vivo as unlabeled CAR-T cells using BLI.

1.8

Acute Lymphoblastic leukemia Mouse Model

There are many models developed to study human leukemia treatments in mice. In this
thesis, we used NOD- Prkdcscid-II2rgtm1Wjl (NSG) mice because of their ability tolerate
injections of human cells144. NSG mice are genetically modified to be immunodeficient
in mature T cells, B cells, and nature killer cells. In addition, they lack other signaling
pathways that are important for proper immune system functioning145. Specifically, the
NOD mutation causes abnormal dendritic cell and macrophage function and removes the
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complement system that is important for innate immunity. Generally, innate immunity is
the first line of defense against pathogens that enter your body. The Prkdcscid severe
combined immunodeficiency (SCID) mutation disrupts the development of mature T and
B cells which comprise the adaptive immune response. The adaptive immune response is
responsible for fighting viral, bacterial, and fungal infections in the body and is required
for memory of infections which helps improve future immune function in the body. The
II2rgtm1Wjl mutation removes functioning interleukin 2 receptor gamma which causes
natural killer (NK) cells to be unable to differentiate and mount a proper immune
response. NK cells recognize infected cells in the body by their lack of MHC I molecule
and kill them to ensure that virally infected cells and early cancer cells do not persist.
They have been shown to assist in the rejection of transplanted tissues, so it is very
important that their function is blocked to allow for human cells to be injected into mice
while avoiding severe side effects such as graft versus host disease and rejection146.
Altogether, these mutations allowed us to implant the NALM6 cell line into mice to form
acute lymphoblastic leukemia bearing mice. NALM6 cells are a human precursor B Cell
leukemia cell line that originated from a 19-year-old man with ALL. NALM6 cells have
been used by many researchers to study leukemia both in vitro and in mouse models147149

. By implanting the NALM6 cells with Matrigel we were able to form solid

subcutaneous tumours in the left hind flank of mice. This technique is ideal as it allows
researchers to study human cancer in a model that can be easily injected with therapeutic
cells and imaged89. Flank tumours were also ideal to minimize the effects of breathing
artifacts in our MR images.
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1.9

Purpose of thesis

This thesis uses 19F-based cellular MRI techniques to detect CAR-T cells in a murine
model of B cell leukemia. The objectives of this work were to determine if PFC+
CAR-T cells could be detected using a 3 T clinical MRI scanner and to evaluate the
performance of PFC+ CAR-T cells compared to unlabeled CAR-T cells using BLI.
Our hypotheses are: 1) 19F based MRI performed on a 3T clinical system will be able
to detect PFC labeled CAR-T cells in a mouse model of leukemia, and 2) PFC+
CAR-T cell cytotoxicity will not be significantly different from unlabeled CAR-T cell
cytotoxicity in vivo. Chapter 2 demonstrates the application of 19F MRI to detect PFC
labeled CAR-T cells in a mouse model of leukemia.

1.10
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2

Visualizing CAR-T Cell Immunotherapy Using 3 Tesla
Fluorine-19 MRI

Purpose: Chimeric antigen receptor (CAR) T cell cancer immunotherapies have shown
remarkable results in patients with hematological malignancies and represent the first
approved genetically modified cellular therapies. However, not all blood cancer patients
respond favourably, serious side effects have been reported, and the treatment of solid
tumours have been a challenge. An imaging tool for visualizing the variety of CAR-T cell
products in use and being explored could provide important patient-specific data on
CAR-T cell location to inform on potential success or failure of treatment as well as offtarget toxicities. Fluorine-19 (19F) magnetic resonance imaging (MRI) allows for the noninvasive detection of 19F perfluorocarbon (PFC) labeled cells. Our objective was to
visualize PFC labeled (PFC+) CAR-T cells in a mouse model of leukemia using clinical
field-strength (3 Tesla) 19F MRI and compare the cytotoxicity of PFC+ versus unlabeled
CAR-T cells.
Procedures: NSG mice (n=17) received subcutaneous injections of CD19+ human B cell
leukemia cells (NALM6) expressing firefly luciferase in their left hind flank (1x106).
Twenty-one days later, each mouse received an intratumoural injection of 10x106 PFC+
CD19-targeted CAR-T cells (n=6), unlabeled CD19-targeted CAR-T cells (n=3), PFC+
untransduced T cells (n=5), or an equivalent volume of saline (n=3). 19F MRI was
performed on mice treated with PFC+ CAR-T cells days 1, 3, and 7 post-treatment.
Bioluminescence imaging (BLI) was performed on all mice days -1, 5, 10, and 14 post
treatment to monitor tumour response.
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Results: PFC+ CAR-T cells were successfully detected in tumours using 19F MRI on
days 1, 3, and 7 post-injection. In vivo BLI data revealed that mice treated with PFC+ or
PFC- CAR-T cells had significantly lower tumour burden by day 14 compared to control
cohorts (p<0.05). Importantly, mice treated with PFC+ CAR-T cells showed equivalent
cytotoxicity compared to mice receiving PFC- CAR-T cells.
Conclusions: Our studies demonstrate that clinical field-strength 19F MRI can be used to
visualize PFC+ CAR-T cells for up to 7 days post intratumoral injection. Importantly,
PFC labeling did not significantly affect in vivo CAR-T cell cytotoxicity. These imaging
tools may have broad applications for tracking emerging CAR-T cell therapies in
preclinical models and may eventually be useful for the detection of CAR-T cells in
patients where localized injection of CAR-T cells is being pursued.

2.1 Introduction
Cancer is a devastating disease with over 220 000 Canadians receiving a cancer diagnosis
each year [1]. Despite enormous effort, cancer continues to be one of the leading causes
of death in the world [2]. There continues to be an urgent need to develop new cancer
therapies that allow for a greater number of cancer patients to survive for significantly
greater lengths of time after their diagnosis. Chimeric antigen receptor (CAR) T cell
therapy was first proposed in 1989 and is now the first genetically modified cellular
therapies to be approved for the treatment of B cell leukemia and lymphoma [3]. CAR-T
cells are produced using a patient’s own T cells that have been isolated and engineered to
express a cancer antigen-specific CAR [4]. The CAR redirects the T cells to bind and kill
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the patient's cancer cells after injection. Multiple CD19-targeted CAR-T cell therapies
have been approved in Canada after showing remarkable results in patients with B cell
malignancies, providing a transformative, potentially curative therapeutic option [5].
Despite the success that CAR-T cells show against B cell malignancies, major challenges
remain. Up to 30% of blood cancer patients do not respond to these therapies, many
patients can relapse, and patients can also suffer from life-threatening side effects such as
cytokine release syndrome or neurotoxicity [6]. In addition, CAR-T cells continue to
show disappointing results against solid tumours [7]. Many of the disparate outcomes
among patients receiving this therapy are thought to be due to CAR-T cells not
proliferating and persisting in the body, proliferating and activating excessively, or
homing to normal organs such as the brain [8]. However, due to the inadequate
information provided by serial blood tests currently used by clinicians, we have limited
evidence about the behaviour of CAR-T cells over time in individual patients. Therefore,
methods to track the fate of adoptively transferred T cells would be extremely valuable
for both pre-clinical and clinical studies to learn about the behaviour of CAR-T cells after
injection.
Cellular imaging is a potential complementary technology to blood tests involving noninvasive imaging of cells labeled with imaging technologies to achieve information on
cell fate after adoptive transfer. Ex-vivo labeling is a particularly invaluable approach for
CAR-T cell therapies as they require ex-vivo processing for production regardless of
whether or not imaging is implemented. The breadth of cellular imaging technologies
available spans from preclinical imaging modalities such as fluorescence and
bioluminescence imaging (BLI) to clinical modalities such as magnetic resonance
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imaging (MRI), photoacoustic tomography, and positron emission tomography (PET) [9].
Importantly, successful PET imaging of intracranially infused cytotoxic T cells coexpressing a PET reporter gene was demonstrated in glioma patients [10], [11].
MRI is also being explored extensively as a clinical cell tracking tool. MRI provides
images with fine spatial resolution and high soft tissue differentiation, uses non-ionizing
radiation that can be beneficial for longitudinal studies, numerous MRI probes and
reporter genes have been developed for ex vivo cell labeling, and MRI is broadly
available within the healthcare system in most developed countries. Currently, most
immune cell tracking studies utilizing MRI have been accomplished by labeling cells
with iron oxide nanoparticles (IONS) [12]. Clinical imaging of ION labeled dendritic
cells in melanoma patients was achieved by De Vries et al in 2005 [13]. IONs allow
labeled cells to be detected with high sensitivity, even single cells in preclinical models,
but detection of the cells can be difficult in locations such as the lungs as IONs cause
hypointensities in images [14]. In contrast, fluorine-19 perfluorocarbons (PFC) are a
tracer agent that is easily taken up by cells and can be detected directly by fluorine-19
(19F) MRI [15]. 19F MRI cell tracking provides positive contrast which enables improved
quantitation in comparison to ION imaging and has high specificity because there is no
detectable endogenous 19F in the body. This technique is clinically relevant as PFCs were
used off label in patients for many years as a blood substitute [16]. In addition, 19F MRI
has been successfully used in the clinic to detect PFC labeled (PFC+) dendritic cells in
patients [17]. Previous preclinical studies have shown the feasibility of labeling CAR-T
cells with PFC and detecting them with high field-strength 19F MRI [18]-[20]. However,
data supporting the ability to image PFC+ CAR-T cells using a clinical field-strength
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scanner is lacking, which is important to demonstrate when assessing if translation of this
technology into patients is feasible. Moreover, in vivo data comparing the cytotoxicity
against tumors of CAR-T cells versus PFC+ CAR-T cells is lacking.
In this study we focused on using

19

F PFC based imaging to monitor CAR-T cells over

time using clinical field-strength 3 Tesla MRI. In addition, we used bioluminescence
imaging (BLI) to evaluate whether labeling CAR-T cells with PFC affects their in vivo
cytotoxicity towards cancer cells. Our results indicate that this technique can reliably
detect PFC+ CAR-T cells post-intratumoural injection using clinical field strengths. We
also show for the first time that PFC labeling does not significantly affect in vivo CAR-T
cell cytotoxicity in a mouse model of leukemia, which is important for potential future
use of this imaging technique in patients.

2.2
2.2.1

Materials and Methods
Cancer Cells and Engineering

A CD19 positive B cell acute lymphoblastic leukemia cell line (NALM6 cells;
Cedarlane) was utilized for this study. NALM6 cells were maintained in RPMI medium
supplemented with 10% fetal bovine serum (Wisent) and 1% antibiotic-antimycotic
(100X; Thermofisher). NALM6 cells were engineered to stably co-express the
fluorescence reporter tdTomato (tdT) and a codon-optimized bioluminescence firefly
luciferase reporter (Luc2) using a lentiviral vector previously constructed in our lab [21].
Cells were transduced with lentiviral vector using polybrene (1.6ug/ml, Sigma Aldrich).
Transduced cells were analyzed and sorted using fluorescence activated cell sorting
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(FACSAria III flow cytometric cell sorter, BD Biosciences), and expanded prior to
downstream use.

2.2.2

Human T Cells and Engineering

Frozen PBMCs from various donors were purchased from StemCell. PBMCs cells were
cultured in ImmunoCult-XF T cell expansion medium (StemCell) supplemented with
100U/mL interleukin-2 (Chiron) and 2µL (55µM) 2-mercaptoethanol (Sigma). T cell
populations were obtained by thawing human PBMCs (StemCell) and activating 1x105
cells per well with 2µL of 4x107 beads/mL Human T-activator CD3/CD28 Dynabeads
(Thermofisher) as outlined in the protocol from Hammill et al. [22]. Twenty-four hours
later, T cells were engineered to co-express a CD19 targeted CAR and green fluorescent
protein (GFP) using a CD19 CAR-GFP lentiviral transfer plasmid expressing a second
generation CD19 targeting CAR containing the 4-1BB co-stimulatory molecule
generously gifted by Drs. Robert Holt and Brad Nelson (University of British Columbia)
using an MOI of 5. Transduced and untransduced T cell populations were then expanded
and evaluated with flow cytometry to evaluate CAR/GFP, CD3, CD4, and CD8
expression. To produce PFC labeled (PFC+) CAR-T cells or PFC+ untransduced T cells
for

19

F MRI, T cell populations were labeled overnight with 5mg/ml Texas Red

fluorescent dye conjugated PFC (CS-ATM DM Red, CelSense) and washed three times
with phosphate buffer saline (PBS) prior to downstream applications.
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2.2.3

In Vitro Imaging

To evaluate the minimum number of PFC+ CAR-T cells that could be detected at 3T,
triplicates of CAR-T cell pellets containing decreasing numbers of labeled cells (2, 1, 0.5,
0.25, 0.1 (x 106) cells) were imaged using

19

F MRI. Samples were made by mixing

labeled and unlabeled CAR-T cells to obtain a total of 2x106 cells per Eppendorf tube, the
Eppendorf tube was then spun down to form pellets, and then topped with 1% agarose
prior to MRI. The resulting samples were imaged at 3T using a clinical GE 3T MR750
system following the same imaging protocols used for in vivo imaging (see below).
Analysis of all 19F MRI images is described further below.
To compare the cytotoxicity of PFC+ and unlabeled CAR-T cells, 5x104 NALM6-tdTFLuc cells were seeded with PFC+ or unlabeled CAR-T cells at increasing effector to
target ratios (1:4, 1:2, 1:1). Twenty-four hours later, 1µL of D-luciferin was added to
each well (30 mg/mL, Syd Labs) and BLI was performed immediately on an IVIS
Lumina XRMS scanner (IVIS Lumina XRMS In Vivo Imaging System, PerkinElmer).
BLI signal was evaluated with region-of-interest (ROI) analysis using LivingImage
Software (Perkin Elmer). Quantification was performed by drawing ROIs over each well
to obtain the average radiance per well (photons/second/mm2/steradian).

2.2.4

Animal models

Animals were cared for in accordance with the standards of the Canadian Council on
Animal Care, and under an approved protocol of the University of Western Ontario’s
Council on Animal Care (2018-150). NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice
(n=17) received subcutaneous injections of 1x106 NALM6-tdT-FLuc cells mixed with 50
ul of Matrigel in their left hind flank. Twenty-one days later, each mouse received an
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intratumoural injection of 10x106 PFC+ CAR-T cells (n=6), unlabeled CAR-T cells
(n=3), PFC+ untransduced T cells (n=5), or an equivalent volume of saline (n=3).

2.2.5

Nuclear magnetic resonance (NMR)

To evaluate the number of average

19

F spins in cells, NMR was performed on samples

containing 1x106 PFC+ CAR-T cells or PFC+ untransduced T cells. To prepare the
samples for NMR, the cells were lysed by adding 10 µl Radioimmunoprecipitation assay
(RIPA) buffer (VWR, Mississauga, CAN), sonicated 3 times, and then underwent 3
freeze-thaw cycles. The lysate was then placed in an NMR tube with 0.1% trifluoroacetic
(TFA) acid and heavy water (D2O).

19

F NMR measurements were performed using a

Varian Inova 400 spectrometer (Varian Inc, Palo Alto, USA) as described by Makela et
al. [23].

2.2.6

In Vivo BLI

BLI was performed on days -1, 5, 10, and 14 post-treatment in all mice. Mice were
anesthetized with 2% isoflurane in oxygen during imaging sessions. Anesthetized mice
received an intraperitoneal injection of 100µL of D-luciferin (30mg/mL) and images
were collected using an IVIS Lumina XRMS scanner for up to 30 minutes. Day -1
images were used as a baseline for tumour burden to determine treatment response after
CAR-T cell, T cell, or saline injections. BLI signal was evaluated with ROI analysis
using LivingImage Software (Perkin Elmer). An ROI was drawn around the whole mouse
and the total flux (photons/sec) was measured to determine the peak signal in the 30minute imaging session. The peak signal for each mouse at each time point was recorded
and used for statistical analysis.
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2.2.7

In Vivo 19F MRI

Mice bearing leukemia tumours that received PFC+ CAR-T cells or PFC+ untransduced
T cells were imaged with

19

F MRI on days 1, 3, and 7 post-treatment. Mice were

anesthetized with 2% isoflurane in oxygen during imaging sessions. 1H and

19

F images

were acquired on a clinical 3T MRI (GE 3T MR750 system, General Electric, ON, CAN)
using a custom built 4.3 x 4.3 cm2 dual tuned 1H/19F surface coil. In vivo 1H and

19

F

images were both acquired with a 3D balanced steady state free precession (bSSFP) pulse
sequence. Two reference tubes of known

19

F concentration (3.33 x 1016 19F/µL) were

imaged alongside the mice for quantification purposes. 1H imaging parameters were: field
of view (FOV) = 60 x 30 mm, matrix size = 150 x 75, slice thickness = 0.4 mm (0.4 x 0.4
x 0.4 mm3 resolution), flip angle (FA) = 20°, bandwidth (BW) = ±31.25 kHz, repetition
time (TR)/ echo time (TE) = 12.8/6.4 ms, phase cycles (PC) = 12, total scan time = 9
minutes.

19

F imaging parameters were: FOV = 60 x 30 mm, matrix = 60 x 30, slice

thickness = 1 mm (1 x 1 x 1 mm3 resolution), FA = 72°, BW = ±10 kHz, TR/TE = 5.6/2.8
ms and 150 NEX, scan time = 27 mins.
19

F images were analyzed using Horos software. The standard deviation (Sdev) of

background signal for each

19

F image was measured by drawing a region of interest

(ROI) in an area of background noise. A minimum threshold of 5 times the Sdev was
used to mask lower amplitude signal and yield a reliable measurement of

19

F signal in

cell pellets, tumors, and reference tubes. This imaging criteria is based on an

19

F signal

with signal-to-noise (SNR) ratio > 5. Total 19F signal in cell pellets, tumors, and reference
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tubes was calculated as mean 19F signal * volume of ROI. 19F content in cell pellets and
tumors was determined by comparing the

19

F signal measured from these ROIs to the

signal measured from the reference tubes (3.33 x 1016 19F/µL).

2.2.8

Histology

Two mice from the PFC+ CAR-T cell treatment group and the PFC+ untransduced T cell
treatment group were euthanized via overdose of isoflurane on day 10 post-treatment.
Their primary tumours were excised, fixed in 4% paraformaldehyde, and cryoprotected
by passaging through a sucrose gradient of 10%, 20%, and 30%. Samples were then
frozen in optimal cutting temperature compound using dry ice and 10 µm sections were
collected using a cryostat (Leica CM350 Cryostat). Tumour sections was stained with
DAPI and imaged using fluorescence microscopy (EVOS FL Auto 2) to detect GFP
expressing CAR-T cells.

2.2.9

Statistics

Statistics were performed using the GraphPad Prism 8 Software. Unpaired t-tests were
performed on the in vitro BLI cytotoxicity assay data to assess the difference between the
cytotoxicity of PFC+ and PFC- CAR-T cells. A simple linear regression was performed
on the in vitro 19F MRI data to assess the correlation between 19F signal and cell number.
A two-way ANOVA with multiple comparisons was performed on the in vivo 19F signal
data to compare between the labeled treatment groups at each time point. A two-way
ANOVA with Tukey’s multiple comparisons was performed on the in vivo BLI data to
assess any differences in the treatment responses observed between treatment groups at
each imaging time point. A nominal p-value less than 0.05 was considered significant.
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2.3
2.3.1

Results
Production and characterization of treatment and target cells

Figure 2.1a shows a representation of the CD19-CAR-GFP plasmid used to make CD19
targeting CAR-T cells and the tdT-FLuc plasmid used to make firefly luciferase
expressing NALM6 cells. Flow cytometry revealed that CAR-T cell populations were
approximately 68.6% CAR/GFP positive after transduction. Further, the CAR-T cell
populations were approximately 97% CD3 positive, 67.5% CD4 positive, and 26.1%
CD8 positive prior to injection. Untransduced T cell populations showed similar
characteristics with approximately 97% CD3 positive cells, 47.6% CD4 positive cells,
and 45.5% CD8 positive cells (Fig 2.1c). After labeling the T cell populations with 5
mg/ml texas red fluorophore-conjugated PFCs overnight, 88.8% of the cells were positive
for uptake of PFC (Fig 2.1d). On average, the labeled T cell populations contained
5.116865×1011
(Fig 2.1b).

19

F/Cell. After transduction, 98.7% of NALM6 cells expressed tdT/Fluc
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Figure 2.1: Production and characterization of CAR-T cells and their target cells.
(a) Diagrams depicting a lentiviral (LV) tdT-FLuc transfer plasmid co-expressing
the tdTomato fluorescent gene and firefly luciferase (FLuc2) bioluminescence
reporter gene for the production of NALM6-tdT-FLuc cells and the LV-CD19CAR-GFP plasmid co-expressing the CD19 targeted second generation CAR and
GFP for the production of CD19 CAR-T cells. (b) Merged histograms showing the
NALM6 cell population before and after transduction with the tdT-FLuc lentivirus.
(c) Bar graph showing the percent expression of CAR/GFP, CD3, CD4, and CD8
markers in CD19-CAR-GFP transduced T cell populations and untransduced T cell
populations (n=3). (d) Merged histograms showing a representative CAR-T cell
population before and after labeling with red fluorescent perfluorocarbons
(CelSense).
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2.3.2

In vitro assessment of PFC labeled CAR-T cells and their
target cells

Figure 2.2 shows the in vitro characterization data for the imaging reporters and CAR-T
cell cytotoxicity. BLI revealed that the NALM6-tdT-Fluc cell line had functional Fluc2
activity (Fig 2.2a). Cytotoxicity assays showed that co-culture with unlabeled CAR-T
cells caused an average of 63.6%, 80.5%, and 94.5% Nalm6-tdT-Fluc cell lysis at
effector to target ratios of 1:4, 1:2, and 1:1, respectively (Fig 2.2a). In comparison, PFC+
CAR-T cells caused an average of 43.3%, 73.7%, and 90.0% Nalm6-tdT-Fluc cell lysis at
effector to target ratios of 1:4, 1:2, and 1:1, respectively. There was no significant
difference in cytotoxicity between unlabeled and PFC+ CAR-T cells at any effector to
target ratio (Fig 2.2b). In vitro 19F MRI of PFC+ CAR-T cell pellets showed that pellets
containing only 12.5% labeled CAR-T cells (2.5x105 PFC+ CAR-T cells) could be
reliably detected at 3T. Quantification of the

19

F spins revealed that there was a strong

positive correlation between 19F signal and labeled cell number (R2=0.8568; p<0.05).
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Figure 2.2: In vitro characterization of the PFC labeled CAR-T cells. (a) BLI
cytotoxicity assay showing the viability of NALM6-tdT-FLuc cells in the presence of
saline (control), unlabeled CAR-T cells (PFC-), or PFC labeled CAR-T cells (PFC+)
at increasing effector to target ratios (n=3). (b) Bar graph showing percent lysis of
the NALM6-tdT-FLuc cells 24 hours after treatment with PFC labeled or unlabeled
CAR-T cells. (c) 19F MRI of PFC labeled CAR-T cell pellets (2x106 total cells)
containing decreasing numbers of labeled CAR-T cells (2, 1, 0.5, 0.25, 0.1 (x106)
cells). (d) Quantification of 19F signal compared to cell number shows a strong
positive correlation (R2=0.8568; p<0.05).
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2.3.3

19

F Cellular MRI Detection of PFC-Labeled T cells in TumorBearing NSG Mice

In vivo detection of PFC+ CAR-T cells using 3T clinical MRI was assessed after
intratumoural injections of 10x106 cells into mice bearing subcutaneous Nalm6-tdT-Fluc
tumours. All mice injected with NALM6-tdT-Fluc cells developed tumours in their left
hind flanks by day 21 post-injection. Figure 2.3 shows representative

19

F images of

tumour bearing mice after intratumoural injections of either PFC+ CAR-T cells or PFC+
T cells. 19F images are overlaid onto 1H images for anatomical reference. In all mice, 19F
signal was present in the tumour on days 1, 3, and 7 post PFC+ cell injection (Fig 2.3a
and 2.3b). The

19

F MRI data shows that the PFC+ T cells and CAR-T cells were

accurately injected intratumourally in all of the treated mice and the persistent 19F signal
suggests that the PFC+ cells remain in the tumour over time. The total number of

19

F

spins for each tumor on days 1, 3, and 7 were quantified and are shown in Figure 2.3c.
The mean number of 19F spins was not significantly different between PFC+ CAR-T cell
treated tumors and PFC+ T cell treated tumours at any time point.
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Figure 2.3: In vivo 19F MRI of leukemia tumour bearing mice treated with 10x106
PFC labeled CAR-T cells (n=6) or 10x106 PFC labeled untransduced T cells (n=5).
19F images are overlaid onto 1H images for anatomical reference. 19F signal is
detected in the tumours over time. Scale bars represent the range of 19F signals. (a)
Representative images from two PFC labeled CAR-T cell treated mice on days 1, 3
and 7 post-treatment. (b) Representative images of a PFC labeled untransduced T
cell treated mouse on days 1, 3, and 7 post-treatment. (c) Quantification shows no
significant differences of 19F signal over time between PFC+ CAR-T cell and PFC+
T cell groups.
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2.3.4

In vivo BLI of leukemia bearing mice treated with CAR-T
cells

To assess whether PFC labeling effected CAR-T cell therapy outcome, BLI images of
NALM6-tdT-Fluc tumour bearing mice were obtained up to 14 days after intratumoural
injections of 10x106 PFC+ CAR-T cells (Fig 2.4a), unlabeled CAR-T cells (Fig 2.4b),
PFC+ T cells (Fig 2.4c), or an equivalent volume of saline (Fig 2.4d). PFC+ and
unlabeled CAR-T cell treated mice showed decreased BLI signal after treatment. PFC+ T
cell and saline treated mice showed continuous increases in BLI signal after treatment.
The total flux from each mouse at each imaging timepoint was quantified and are shown
in Figure 2.4e. Mice treated with PFC+ CAR-T cells had significantly lower BLI signal
by day 14 compared to mice treated with PFC+ T cells or saline (p<0.0001, p<0.0001).
There were no significant differences between the BLI signal in mice treated with saline
or PFC+ T cells at any time point. Importantly, there were no significant differences in
BLI signal between mice treated with unlabeled CAR-T cells compared to mice treated
with PFC+ CAR-T cells at any time point.
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Figure 2.4: In vivo BLI of firefly luciferase expressing NALM6 tumour bearing mice
days -1, 5, 10, and 14 post-treatment with intratumoural injections of 10x106 PFC
labeled CAR-T cells (n=6), unlabeled CAR-T cells (n=3), PFC labeled T cells (n=5),
or and equivalent volume of saline (n=3). (a) Representative images of a PFC
labeled CAR-T cell treated mouse showing a decrease in tumour burden over time.
(b) Representative images of an unlabeled CAR-T treated mouse showing a decrease
in tumour burden over time. (c) Representative images of a PFC labeled T cell
treated mouse showing increases in tumour burden over time. (d) Representative
images of a saline treated mouse showing increases in tumour burden over time. (e)
Quantitation of BLI signal over time showing significant differences between PFC
labeled CAR-T cell treated mice compared to PFC labeled T cell and saline treated
mice on day 14 (P<0.0001 and p<0.0001). There is no significant difference between
labeled and unlabeled CAR-T cell signal at any timepoint post-treatment.
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2.3.5

Histology

Tumours from mice that received intratumoural injections of PFC+ CAR-T cells or PFC+
T cells were excised on day 10 post-treatment and analyzed to detect the presence or
absence of CAR-T cells. Histological analysis confirmed that GFP positive CAR-T cells
were still present in PFC+ CAR-T cell treated tumours on day 10 post injection (Fig
2.5a). No GFP positive cells were detected in tumours treated with PFC+ T cells (Fig
2.5b).
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Figure 2.5: Histological analysis of GFP expression in a murine tumour treated with
PFC+ GFP expressing CAR-T cells or a murine tumour treated with PFC+
untransduced T cells. (a) Images showing GFP positive CAR-T cells in the tumour
treated with PFC+ CAR-T cells 10 days post intratumoural injection. (b) Images
showing no GFP positive cells in tumours treated with PFC+ untransduced T cells
10 days post intratumoural injection. Images were taken at 20X magnification.
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2.4

Discussion

CAR-T cell therapies have shown tremendous promise in clinical trials against B cell
malignancies. Despite these successes, there are still many limitations to overcome
including overcoming their potential to causes serious side effects and increasing their
efficacy in some patients with hematological malignancies and patients with solid
tumours. Studies have shown that intratumoural injections of CAR-T cells may improve
the treatment outcome in models of solid tumours [24], [25]. One of the main barriers in
intratumoural treatments is ensuring that the injection is administered accurately to
tumours that may be different sizes and in different locations across patients. Acquiring
adequate information on cell location and persistence after injection may improve
intratumoural treatments by ensuring that each patient receives the therapy in the correct
location. In this study, we demonstrate that 19F MRI at 3T provides information on PFC
labeled CAR-T cell location and persistence after injection into mice bearing NALM6tdT-FLuc tumours. Importantly, we saw no significant effect on CAR-T cell treatment
due to PFC labeling.
Clinical translation of cell tracking requires a safe cell label that can be detected with
imaging devices that are commonly found in hospitals. PET has been used in
combination with clinically relevant radiotracers in many studies to track immune cells
with high sensitivity [10],[26],[27]. Unfortunately, concerns about cost, half-life, and
radioactive dose may limit longitudinal cell tracking studies using PET [28]. In contrast,
MRI uses non-ionizing radiation which is ideal for longitudinal cell tracking studies as
radiation dose is not of concern. For this reason, we chose to use 19F MRI as our imaging
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modality and 19F PFCs as our cell label because these are both clinically applicable and,
in combination, allow for direct cell detection and quantification. CAR-T cells had been
successfully labeled with PFCs for detection with 19F MRI in the past, but these studies
used field strengths well above clinical field strengths to enhance 19F signal [18], [19]. In
addition, these studies used CAR-T cells labeled with PFC nanoemulsions that are not, at
this time, commercially available nor manufactured in a manner acceptable for human
use. We demonstrated that functioning CAR-T cells could be detected using 3T clinical
MRI using a surface coil and SNR optimized bSSFP sequence after labeling with
commercially available PFC, which is also available in GMP form for clinical translation.
Additionally, we were able to perform the imaging using a clinically feasible scan time of
approximately 9 minutes for the 1H scan and 27 minutes for the 19F scan.
Our phenotyping results for PFC+ CAR-T cells shown in Figure 1, agree with previous
studies showing that CD8 expressing cells make up approximately 1/3 of the population
and CD4 expressing cells make up approximately 2/3 of the population [19], [20]. Our
cell labeling allowed us to image down to 250 000 cells in vitro which agrees with
previously published results suggesting that thousands of PFC+ cells are needed per
voxel to achieve detection [23]. Our in vivo imaging of mice treated with PFC+ T or
CAR-T cells showed that 19F signal could be detected in every tumour on days 1, 3 and 7
post treatment. Our findings on PFC+ CAR-T cell detection after intratumoural injection
are similar to recent results published by Chapelin et al. which looked at PFC+ CAR-T
cells up to day 10 post intratumoural injection in a mouse model of glioma using an
11.7T MRI scanner [18]. The 19F signal was consistent over time and suggested that the
CAR-T cells were viable and persisting in the tumour site. We also did not see significant
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differences between the

19

F signal detected in mice receiving PFC+ CAR-T cells

compared to PFC+ T cells. This is consistent with their work and may be because T cells
are surviving and remaining in the tumour site in both treatment groups.
We chose to complement our 19F MRI CAR-T cell detection with BLI to assess treatment
response in our mice and determine if PFC labeling influenced in vivo CAR-T cell
cytotoxicity. Our in vitro results showed no significant differences in cytotoxicity
between labeled and unlabeled CAR-T cells, similar to previous work [18]. In addition,
previous PFC+ CAR-T cell tracking studies have shown that labeled CAR-T cells cause
cytotoxicity against glioma in vivo. However, to our knowledge no studies have evaluated
PFC+ CAR-T cell in vivo cytotoxicity compared to unlabeled CAR-T cell cytotoxicity.
BLI of luciferase-expressing tumors over time in mice treated with both PFC+ CAR-T
cells and unlabeled CAR-T cells demonstrated that PFC labeling does not significantly
affect CAR-T cell in vivo cytotoxicity in this model.
There are still limitations to our cell detection method including

19

F MRI being less

sensitive compared to clinical imaging modalities such as PET and cell division
preventing accurate measures of cell number over time [29]. These limitations are
especially important when working with T cells because they are small and nonphagocytic which makes them more difficult to label. Nevertheless, in current clinical
studies testing intratumourally injected CAR-T cells, patients receive up to 1x1010 CART cells, which is well above the detection limit of

19

F MRI [30]. One advantage of

19

F

MRI is that it is quantitative and the number of cells in a given region can be estimated
using in vitro NMR data to determine the amount of 19F per cell. This method can be used
to quantify cell numbers early after injection. However, it is important to point out that
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this method is not as reliable for quantifying CAR-T cell numbers over time, as CAR-T
cells have been shown to proliferate significantly after CAR interaction with their
respective antigen [31]. During cell division, the PFC label should be divided between
daughter cells. If these cells do not remain in the same voxels, this may decrease the 19F
signal in an individual voxel below the detection limit, which would result in an
underestimate of the number of CAR-T cells. Moreover, if the cells remain in the same
voxel this would still underestimate the number of CAR-T cells based on 19F spins. There
is also the potential for background signal caused by macrophages taking up PFCs that
are lost when labeled cells die after injection. However, studies indicate that when
labeled cells die the PFC is most likely broken down and released through the liver and
then exhaled using the reticuloendothelial system [32]. Considering these limitations, it is
therefore important to not overinterpret the

19

F signal as the number of viable cells at

extended periods after adoptive transfer, particularly in highly dividing cell populations.
A complementary imaging tool such as reporter genes, which are passed to daughter
cells, would allow for both highly sensitive short-term imaging with 19F PFCs and longterm cell viability imaging with a reporter gene [33], [34]. We are currently exploring the
usefulness of this combination of cellular imaging technologies for tracking CAR-T cells
in preclinical cancer models.
Currently, our system would be useful for detecting CAR-T cells after intratumoural
injections into easily accessible tumours such as glioblastoma, metastatic colorectal
cancer, and metastatic breast cancer24,25,31. It would be interesting to try imaging
intravenously injected CAR-T cells in an animal model at clinical MRI field strengths in
the future to determine if clinical-field strength imaging of intravenously administered
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CAR-T cells would be feasible. Future work focusing on the development of larger
radiofrequency coils for dual 1H and

19

F MRI would also help advance this field.

However, even if this is not feasible due to lack of sensitivity, it will still be valuable to
continue to explore and develop 19F MRI of PFC-labeled CAR-T cells after intratumoral
injections. In this case, localized coils with high sensitivity like the one used in our study
would be valuable.
Conclusions: We report that PFC+ CAR-T cells can be detected over time with 19F MRI
using a 3T clinical field strength scanner. In addition, we show that PFC labeling does
significantly impact the in vivo treatment response of CAR-T cells in this model, as
shown by longitudinal BLI.

19

F MRI is a useful tool for determining the location and

persistence of CAR-T cells in tumours after localized injection and may have utility for
tracking systemically administered cells in particular tumor types. This imaging tool may
be useful for optimizing current CAR-T cell therapies and may have broad applications
for evaluating emerging CAR-T cell formulations in vivo.

2.5
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Chapter 3

3

Summary and Future Work

This chapter summarizes the experimental findings, limitations, and future work
associated with this thesis.

3.1 Discussions and Conclusions
Despite strong evidence supporting CD19 targeting CAR-T cell therapies as an ideal
cancer treatment for patients with B cell malignancies, there is still the potential for
severe side effects and poor treatment responses in some patients1. Optimizing CAR-T
cell therapies and mitigating their side effects could aid in the widespread clinical
adaptation of these therapies. Knowledge of CAR-T cell biodistribution and persistence
after injection is crucial to learn more about their behaviour during side effects and poor
treatment outcomes. Molecular imaging techniques could complement current clinical
blood tests to provide real time information on the locations and numbers of CAR-T cells
in important sites in the body such as tumours or off target organs. In this thesis, 19F MRI
was used to detect PFC+ CAR-T cells in a mouse model of leukemia. Below is a
summary of the results found in this study.
In Chapter 2, mice bearing luciferase expressing human B cell leukemia tumours were
intratumorally injected with PFC+ CD19 targeting CAR-T cells and imaged over time
with BLI and

19

F MRI. The leukemia cells express CD19 which allows them to be

targeted by the CD19 targeting CAR-T cells.
the number of

19

19

F MRI data was quantified to determine

F spins in each tumour over time. BLI data was analyzed to assess the
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cancer treatment response in mice administered PFC+ CAR-T cells compared to mice
that received unlabeled CAR-T cells. The main findings were:
1. PFC+ CAR-T cells could be detected in tumours up to 7 days after injection using
a 3 T clinical MR scanner and custom dual tuned surface coil designed for use in
humans.
2. Quantification of the BLI data showed that PFC+ CAR-T cells show no
significant difference in cancer treatment response in vivo compared to unlabeled
CAR-T cells.
These findings present important evidence that

19

F 3T MRI could be a useful tool to

detect PFC+ CAR-T cells during clinical trials exploring intratumoural injections of
CAR-T cells. This method may provide information on the location of adoptively
transferred cells to ensure that the injection was successfully administered into a tumour
and that CAR-T cells persist in the tumour during the first week of treatment. In many
cases, a limitation of

19

F MRI is the low sensitivity. In our study, we detected strong

signal in the tumours even at the latest timepoint of day 7 using a clinically relevant scan
time highlighting the potential for this method in the clinic.
There are currently three other papers that have PFC labeled CAR-T cells and detected
them with 19F NMR or MRI. In 2017, Chapelin et al. established PFC labeling techniques
for CAR-T cells and ensured that the label did not affect T cell phenotype2. In 2019,
Hingorani et al. successfully imaged PFC+ CAR-T cells for the first time using 19F MRI
two hours after an intratumoral injection into mice bearing glioma tumours3. Finally, in
2021 Chapelin et al. imaged intratumourally administered PFC+ CAR-T cells up to 10
days post-injection for the first time in a mouse model of glioblastoma4. These studies all
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contributed important milestones to the implementation of 19F MRI for studying CAR-T
cell therapies. One limitation that is common to all of these studies is that they relied on
high field strength MR scanners (e.g., 11.7T) that are currently well above clinical
standards. The work in this thesis successfully implemented PFC+ CAR-T cell detection
using a 3T clinical MR scanner and RF surface coil designed for human use for the first
time. Further, this is the first comparison of PFC labeled CAR-T cell and unlabeled CART cell cytotoxicity in vivo using BLI, which is important to show before PFC labeling and
19

F MRI could be translated to the clinic. It is our hope that these findings support the use

of

19

F MRI for clinical CAR-T cell tracking to achieve patient specific information on

CAR-T cell location after adoptive transfer.

3.2

3.2.1

Challenges and Limitations

COVID-19 Pandemic

The COVID-19 pandemic was a unique challenge for graduate students over the past
year. I recognize that the pandemic has had more extreme impacts on other populations
and that overall, I was lucky to have this stable position with the University during this
time. It was challenging to complete research activities during the lockdowns. I did not
have access to the laboratory from Mid-March 2020 until June 2020 which meant that I
could not make any progress on my project. In addition, access to the laboratory and
research staff has continued to be reduced since we returned to campus in June-August
2020 due to strict safety measures put in place to stop the spread of COVID-19. This has
caused significant delays in the completion of my project, but I was still able to complete
most of the experiments that we had planned and my thesis during this time.

89

3.2.2

T cell detection challenges with 19F MRI

Currently, 19F MRI is less sensitive than many other forms of molecular imaging such as
iron oxide nanoparticle (ION) imaging with MRI or PET5, 6. The sensitivity of 19F MRI is
reliant on how well the cells are labeled, the imaging sequence chosen, the MR field
strength, and the RF coil used7. The uptake of PFC by T cells is lower when compared to
larger, more endocytic/phagocytic cell populations such as dendritic cells or monocytes8.
This means that the signal obtained from labeled T cell populations will be lower per cell
compared to other therapeutic cell populations. In addition, when CAR-T cells are
activated by cancer cells they proliferate extensively to mount a proper response9. As cell
division occurs, the PFCs are divided between the daughter cells, diluting the amount of
label in each cell. This causes the amount of 19F per voxel to decrease over time resulting
in a decrease in signal over time. Eventually, with cell division, the labeled cells will fall
below the detection limit of 19F MRI. Regardless, using the commercially available PFC
CelSense, BSSFP pulse sequence, 3T MRI, and a human dual tuned surface coil we were
able to clearly detect 10 million PFC+ CAR-T cells over time after an intratumoural
injection into mice bearing leukemia tumours. Clinical trials using intratumoral or local
delivery methods for CAR-T cells should expect that they would be able to detect the
injected cells at clinical doses as well.
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3.2.3

Requirements for translating 19F MRI to the clinic

Implementing

19

F MRI cell tracking in a clinical setting would require specialized

equipment to perform dual 1H and

19

F imaging. Many hospitals already have an MR

scanner which can be used for these imaging applications, but they would need to obtain
a dual tuned RF coil for

19

F MRI and have multi-nuclear imaging capabilities. In

addition, the RF coil that was used in this study could easily cover the flank tumours on
mice without any depth concerns. Unfortunately, as

19

F MRI is moved towards patient

imaging the 4.3cm diameter and depth limitations of the surface coil will reduce the
number of studies that could be performed to track cell populations in patients. During
the only clinical trial that used 19F MRI to image labeled cells in patients, they used a 7
cm diameter surface coil10. They successfully imaged and quantified the number of
intradermally injected PFC+ dendritic cells in two patients enrolled in a dendritic cell
vaccine study. This data suggests that clinical imaging of

19

F PFCs in subcutaneous

tumours such as breast cancer or prostate cancer should be possible.

In addition, there has still not been a study to determine whether intravenously (IV)
injected PFC labeled CAR-T cells can be detected at clinical MR field strengths. As most
clinical trials administer CAR-T cells IV, it is important to determine if it is possible to
detect CAR-T cells as they traffic to different locations in the body following this
injection route. Imaging at 3 T would limit the sensitivity of 19F MRI compared to higher
field strength imaging, but the study in this thesis showed that as few as 2.5x105 cells
could be detected in vitro. In most studies, between 1x106-1x108 CAR-T cells are
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injected per kg of body weight into patients which should improve the chances of
detecting cells that traffic to certain locations in the body.
Finally, the lower sensitivity of

19

F MRI may require a higher number of excitations

(NEX) to be used during an imaging session leading to longer scan times. Most current
MRI scan times for patients are 30 to 40 minutes to avoid patient discomfort11. In our
study, the pre-clinical scan times were 9 minutes for the 1H scan followed by 27 minutes
for the

19

F scan. This would be feasible in the clinic but as

19

F MRI is moved towards

patients they may need to increase these scan times to accommodate for the depth of the
PFCs in the body and the RF coil that is being used.

3.2.4

Quantification Inaccuracies

As mentioned in chapter 1 of this thesis, PFC labels are taken up by cells through
endocytosis and held in the cytoplasm as long as the cell remains viable12. Unfortunately,
when cell death occurs the labeled cell can be taken up by macrophages and persist in
tissues leading to background signal. This phenomenon is known as “bystander cell
uptake” and can cause false positives in

19

F images. Although this cannot be avoided,

Fink et al. have previously confirmed that the

19

F signal in their model was being

produced by the PFC+ PBMCs that were injected instead of macrophages13.
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In addition to signal accuracy concerns, there are also limitations associated with
quantifying the number of cells that are detected in an 19F image. As described in chapter
1, an advantage of

19

F MRI is that it is quantitative and can be used to determine the

number of labeled cells in a subject. Most studies that have used

19

F MRI to track ex

vivo PFC+ cells have used information from 19F NMR and the signal obtained from 19F
images to determine the number of cells in a given region. This data may be accurate at
early imaging timepoints, especially if the cells do not divide or divide very slowly.
Unfortunately, with cell populations like CAR-T cells, activation causes extensive
proliferation and dilution of the PFC label. This leads to a decrease in detected 19F signal
over time which would indicate that there were fewer cells in a given location. In reality,
there would in fact be many more cells in the body over time due to CAR-T cell
expansion. For this reason, 19F MRI cannot accurately be used to quantify the number of
CAR-T cells in a tumour over time. Other groups have still used

19

F MRI cell

quantification to their advantage by determining the accuracy of their intratumoural
injections immediately following adoptive transfer. Hingorani et al. for example
determined that they could detect approximately 100% of the cells that they injected 2
hours after injection into a mouse model of glioma using 19F MRI cell quantification14.

3.3

Future work

Future work will use 19F MRI cell detection to study CAR-T cell location and persistence
in animal solid tumour models such as breast cancer. Additionally, future work will look
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into combined

19

F MRI and reporter gene-based CAR-T cell tracking to gain more

information on CAR-T cell behaviour in treatment models and determine the best method
for clinical cell detection.

Explore 19F MRI for intratumourally injected cancers such as
breast or prostate cancer

3.3.1

Intratumoural or local delivery of CAR-T cells has been proposed as a method to improve
the efficacy of CAR-T cell therapies against solid tumours. Multiple pre-clinical studies
have showed that local delivery of CAR-T cells is an effective method for treating
tumours and may even improve the therapeutic outcome in animal models compared to
other injection methods15-17. In addition, there are clinical trials underway to test
intratumorally injected CAR-T cells in patients with breast cancer and head and neck
cancer and intracranially injected CAR-T cells in patients with brain cancer18,19.
Unfortunately, studies have noted that local delivery is more difficult than IV delivery as
tumours may be different sizes and in different locations making it harder to accurately
inject the therapy20. An inaccurate injection may have large implications on the efficacy
of the treatment and the validity of efficacy studies in both pre-clinical and clinical trials.
In the work presented in this thesis, we were able to demonstrate that CAR-T cells can be
efficiently labeled with PFC and detected in leukemia tumours over time after
intratumoural injections. Future work will look at using 19F MRI to detect CAR-T cells in
relevant solid tumour models such as breast cancer or breast cancer brain metastases. The
use of

19

F MRI in studies testing the efficacy of intratumourally injected CAR-T cells

would provide important information on the location and persistence of CAR-T cells in
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the tumours. It could also be used as a metric to ensure that the intratumoural injections
are accurate and successfully reach the targeted location in the body. This information
may be useful for determining why some subjects do not respond to CAR-T cells.
Additionally, it may help in determining which injection route is best for each cancer
type that is being targeted by the therapy.

Dual 19F and reporter gene-based cell tracking of CAR-T
cells using MRI

3.3.2

Reporter gene-based imaging is valuable for studying highly proliferative cell
populations as it relies on stable expression of a reporter gene. Stable reporter gene
expression allows for longitudinal cell tracking because the reporter gene is passed onto
daughter cells during cell division, leading to increased signal as cells proliferate. In
addition, by co-expressing CARs and reporter genes in the same construct, reporter genes
can be introduced to T cells using the same protocols that are already in place to generate
current CAR-T cell therapies in the clinic. Many groups have started to employ reporter
gene-based imaging methods to try to circumvent the signal loss that occurs with labels
during cell division21-23. Wu et al. developed a human derived MRI reporter gene called
organic anion transporting polypeptide 1B3 (OATP1B3) that can be used in combination
with

the

clinically

approved

contrast

agent

gadolinium

ethoxybenzyl

diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)24. This method of imaging may be
able to track dividing cells for longer periods of time due to stable gene expression. Using
this cell detection technique in CAR-T cells in combination with

19

F MRI will provide

both short term and long-term information on cell location, viability, and proliferation
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using non-invasive imaging. We posit that this will also be a valuable technique to
compare

19

F MRI of PFC labeled cells against OATP1B3 reporter gene imaging of

engineered cells. All together, these imaging techniques will provide more information
on CAR-T cell behaviour after injection that may provide insight into making safer and
more effective CAR-T cell therapies. Additionally, these techniques will get us closer to
clinical cell tracking ventures.

3.4
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